Carla Arnau del Valle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carla Arnau del Valle has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Maria Jose Marin
School of Chemistry, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
4 shared publications - Huang-Chiao Huang
Fischell Department of Bioengineering, University of Maryland, College Park, USA
2 shared publications - María Paz Muñoz
School of Chemistry, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
2 shared publications - Brydie A. Thomas-Moore
Iceni Glycoscience Ltd., Norwich Research Park, Norwich, NR4 7TJ, UK
1 shared publication - Clara Vazquez-Martel
Heidelberg University
1 shared publication - Dana M. Roque
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Division of Gynecologic Oncology, University of Maryland School of Medicine, Baltimore, Maryland
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
High-Resolution 3D Laser Printing of Microalgae-Derived Materials for Photodynamic Therapy
Photodynamic therapy (PDT) offers localized, controllable cancer treatment through reactive oxygen species (ROS) generated by light-activated photosensitizers. Three-dimensional (3D) printing of PDT-active materials has emerged as a powerful tool for fabricating customized structures with controlled architecture and composition. However, conventional PDT materials often require complex, multi-step syntheses with low yields. Consequently, integrating natural photosensitizers into biocompatible matrices represents a crucial step towards sustainable PDT. Here, microalgae-derived materials are investigated to fabricate high-resolution scaffolds via 3D laser printing while retaining the intrinsic photoactive properties of chlorophyll. Within these matrices, native chlorophyll derivatives fulfill a triple light-induced function: driving microalgal lipid biosynthesis, initiating additive-free 3D laser printing, and acting as immobilized photosensitizers. Fluorometric assays confirm robust ROS generation upon red-light irradiation of the 3D printed microalgae-derived material. The photodynamic efficacy of these scaffolds is evaluated in melanoma cells to demonstrate their therapeutic potential. In vitro studies reveal significantly reduced cell viability upon irradiation, while maintaining cytocompatibility under dark conditions. Furthermore, the microalgae-derived materials enable the fabrication of scaffolds with varied complex geometries and feature sizes while retaining photodynamic activity. These findings demonstrate a highly versatile, biobased strategy combining natural photosensitizers with 3D laser printing to produce functional platforms for precision PDT.
- 5 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessHigh-Resolution 3D Laser Printing of Microalgae-Derived Materials for Photodynamic Therapy
Photodynamic therapy (PDT) offers localized, controllable cancer treatment through reactive oxygen species (ROS) generated by light-activated photosensitizers. Three-dimensional (3D) printing of PDT-active materials has emerged as a powerful tool for fabricating customized structures with controlled architecture and composition. However, conventional PDT materials often require complex, multi-step syntheses with low yields. Consequently, integrating natural photosensitizers into biocompatible matrices represents a crucial step towards sustainable PDT. Here, microalgae-derived materials are investigated to fabricate high-resolution scaffolds via 3D laser printing while retaining the intrinsic photoactive properties of chlorophyll. Within these matrices, native chlorophyll derivatives fulfill a triple light-induced function: driving microalgal lipid biosynthesis, initiating additive-free 3D laser printing, and acting as immobilized photosensitizers. Fluorometric assays confirm robust ROS generation upon red-light irradiation of the 3D printed microalgae-derived material. The photodynamic efficacy of these scaffolds is evaluated in melanoma cells to demonstrate their therapeutic potential. In vitro studies reveal significantly reduced cell viability upon irradiation, while maintaining cytocompatibility under dark conditions. Furthermore, the microalgae-derived materials enable the fabrication of scaffolds with varied complex geometries and feature sizes while retaining photodynamic activity. These findings demonstrate a highly versatile, biobased strategy combining natural photosensitizers with 3D laser printing to produce functional platforms for precision PDT.
- Open Access
- 27 March 2026
- Published by Wiley in Advanced Therapeutics
- Vol. 9 (4)
Light‐Triggered Antibody‐Photosensitizer Conjugates Disrupt P‐Glycoprotein Function to Reverse Multidrug Resistance
Ovarian cancer is the deadliest gynecologic disease with a 5‐year survival rate of ∼30% for advanced stages. A major cause of poor prognosis is the development of chemoresistance, which accounts for 90% of ovarian cancer deaths. A key mediator of this resistance is the expression of ATP‐binding cassette (ABC) drug efflux transporters, particularly P‐glycoprotein (P‐gp, also known as ABCB1), which is upregulated in response to treatment and confers the development of multidrug resistance (MDR). Existing small molecule inhibitors of P‐gp often lack cancer selectivity and are thus associated with normal tissue toxicity. Our team has previously demonstrated that photodynamic therapy (PDT), employing the FDA‐approved benzoporphyrin derivative (BPD) photosensitizer, can effectively inhibit ABC transporters in cancer cells. PDT is a localized treatment that utilizes a photosensitizer, a light‐activated drug, and light of a specific wavelength to generate cytotoxic reactive oxygen species. However, BPD alone lacks cancer selectivity, making it less suitable for addressing disseminated tumors, such as those found in advanced‐stage ovarian cancer. To improve cancer selectivity, we conjugated BPD to an anti‐epidermal growth factor receptor (EGFR)‐targeting monoclonal antibody (cetuximab) to form a photoimmunoconjugate (PIC). We demonstrate that PIC evades and inhibits P‐gp‐mediated efflux in chemoresistant ovarian cancer cells. These findings highlight the role of PICs and the importance of understanding their interactions with ABC transporters in combating multidrug resistance in advanced‐stage cancer.
- 27 March 2026
- Published by Wiley in Advanced Therapeutics
- Vol. 9 (4)
Open AccessLight‐Triggered Antibody‐Photosensitizer Conjugates Disrupt P‐Glycoprotein Function to Reverse Multidrug Resistance
Ovarian cancer is the deadliest gynecologic disease with a 5‐year survival rate of ∼30% for advanced stages. A major cause of poor prognosis is the development of chemoresistance, which accounts for 90% of ovarian cancer deaths. A key mediator of this resistance is the expression of ATP‐binding cassette (ABC) drug efflux transporters, particularly P‐glycoprotein (P‐gp, also known as ABCB1), which is upregulated in response to treatment and confers the development of multidrug resistance (MDR). Existing small molecule inhibitors of P‐gp often lack cancer selectivity and are thus associated with normal tissue toxicity. Our team has previously demonstrated that photodynamic therapy (PDT), employing the FDA‐approved benzoporphyrin derivative (BPD) photosensitizer, can effectively inhibit ABC transporters in cancer cells. PDT is a localized treatment that utilizes a photosensitizer, a light‐activated drug, and light of a specific wavelength to generate cytotoxic reactive oxygen species. However, BPD alone lacks cancer selectivity, making it less suitable for addressing disseminated tumors, such as those found in advanced‐stage ovarian cancer. To improve cancer selectivity, we conjugated BPD to an anti‐epidermal growth factor receptor (EGFR)‐targeting monoclonal antibody (cetuximab) to form a photoimmunoconjugate (PIC). We demonstrate that PIC evades and inhibits P‐gp‐mediated efflux in chemoresistant ovarian cancer cells. These findings highlight the role of PICs and the importance of understanding their interactions with ABC transporters in combating multidrug resistance in advanced‐stage cancer.
- Open Access
- 14 May 2025
- Published by Wiley in Bioengineering & Translational Medicine
Self‐assembly of verteporfin dimers into folate receptor‐targeted lipid nanoparticles for photodynamic therapy of ovarian cancer
Photodynamic therapy (PDT) is a minimally invasive treatment that involves the administration of a light‐activatable drug followed by light activation of the lesion to produce reactive oxygen species that kill cancer cells. Visudyne®, a liposomal formulation of benzoporphyrin derivative (BPD) photosensitizer, is clinically approved for PDT of ocular diseases and is now being tested for PDT and imaging of pancreatic, brain, and other cancers. While Visudyne® improves the pharmacokinetics of BPD, it lacks treatment selectivity. To reduce PDT‐associated side effects such as skin and bowel toxicity while enhancing therapeutic outcomes, developing cancer‐targeted BPD nanotechnology is essential. Many cancers are characterized by overexpression of folate receptor (FR) and present high levels of glutathione (GSH). Here, we report the synthesis of a dimeric‐BPD (dBPD) activatable by red light for PDT and imaging of cancer cells. Self‐assembled lipid nanoparticles (NPs) are developed by the aggregation of dBPD and further functionalized with FA (FA‐dBPD‐NPs) and with drug release capability via cleavage of the disulfide linkers through GSH. The FA‐dBPD‐NPs present high drug payload, GSH‐triggered release effect, FRs overexpressing cell targeting, endoplasmic reticulum accumulation, and effective PDT in ovarian cancer cells.
- 14 May 2025
- Published by Wiley in Bioengineering & Translational Medicine
Open AccessSelf‐assembly of verteporfin dimers into folate receptor‐targeted lipid nanoparticles for photodynamic therapy of ovarian cancer
Photodynamic therapy (PDT) is a minimally invasive treatment that involves the administration of a light‐activatable drug followed by light activation of the lesion to produce reactive oxygen species that kill cancer cells. Visudyne®, a liposomal formulation of benzoporphyrin derivative (BPD) photosensitizer, is clinically approved for PDT of ocular diseases and is now being tested for PDT and imaging of pancreatic, brain, and other cancers. While Visudyne® improves the pharmacokinetics of BPD, it lacks treatment selectivity. To reduce PDT‐associated side effects such as skin and bowel toxicity while enhancing therapeutic outcomes, developing cancer‐targeted BPD nanotechnology is essential. Many cancers are characterized by overexpression of folate receptor (FR) and present high levels of glutathione (GSH). Here, we report the synthesis of a dimeric‐BPD (dBPD) activatable by red light for PDT and imaging of cancer cells. Self‐assembled lipid nanoparticles (NPs) are developed by the aggregation of dBPD and further functionalized with FA (FA‐dBPD‐NPs) and with drug release capability via cleavage of the disulfide linkers through GSH. The FA‐dBPD‐NPs present high drug payload, GSH‐triggered release effect, FRs overexpressing cell targeting, endoplasmic reticulum accumulation, and effective PDT in ovarian cancer cells.
- Open Access
- 8 March 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (15) , 3387-3396
Gold nanoparticle-based two-photon fluorescent nanoprobe for monitoring intracellular nitric oxide levels
Nitric oxide (NO) plays an important role in the regulation of the immune, cardiovascular and nervous systems. Consequently, being able to monitor and quantify intracellular NO levels would provide a greater understanding of the implications of this molecule in the different biological processes, including, for example, in cancer. Here, we report a broadly applicable two-photon excitable fluorescent nanoprobe able to detect and potentially quantify NO levels in an extensive range of cellular environments. The nanoprobe consists of a thiolated photoinduced electron transfer-based two=photon fluorescent probe attached onto the surface of 2.4 ± 0.7 nm gold nanoparticles (DANPY-NO@AuNPs). The nanoprobe, which can be synthesised in a reproducible manner and exhibits great stability when stored at room temperature, is able to selectively detect NO in solution, with a dynamic range up to 150 μM, and at pH values of biological relevance. DANPY-NO@AuNPs were able to selectively detect endogenous NO in RAW264.7γ NO− macrophages and THP-1 human leukemic cells; and endogenous and exogenous NO in endothelial cells. The nanoprobe accumulated in the acidic organelles of the tested cell lines showing negligible toxicity. Importantly, DANPY-NO@AuNPs showed potential to quantify intracellular NO concentrations in MDA-MB-231 breast cancer cells. The biological evaluation of the nanoprobe was undertaken using confocal laser scanning (images and intracellular emission spectra) and multiphoton microscopies, and flow cytometry. Based on their excellent sensitivity and stability, and outstanding versatility, DANPY-NO@AuNPs can be applied for the spatiotemporal monitoring of in vitro and in vivo NO levels.
- 8 March 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (15) , 3387-3396
Open AccessGold nanoparticle-based two-photon fluorescent nanoprobe for monitoring intracellular nitric oxide levels
Nitric oxide (NO) plays an important role in the regulation of the immune, cardiovascular and nervous systems. Consequently, being able to monitor and quantify intracellular NO levels would provide a greater understanding of the implications of this molecule in the different biological processes, including, for example, in cancer. Here, we report a broadly applicable two-photon excitable fluorescent nanoprobe able to detect and potentially quantify NO levels in an extensive range of cellular environments. The nanoprobe consists of a thiolated photoinduced electron transfer-based two=photon fluorescent probe attached onto the surface of 2.4 ± 0.7 nm gold nanoparticles (DANPY-NO@AuNPs). The nanoprobe, which can be synthesised in a reproducible manner and exhibits great stability when stored at room temperature, is able to selectively detect NO in solution, with a dynamic range up to 150 μM, and at pH values of biological relevance. DANPY-NO@AuNPs were able to selectively detect endogenous NO in RAW264.7γ NO− macrophages and THP-1 human leukemic cells; and endogenous and exogenous NO in endothelial cells. The nanoprobe accumulated in the acidic organelles of the tested cell lines showing negligible toxicity. Importantly, DANPY-NO@AuNPs showed potential to quantify intracellular NO concentrations in MDA-MB-231 breast cancer cells. The biological evaluation of the nanoprobe was undertaken using confocal laser scanning (images and intracellular emission spectra) and multiphoton microscopies, and flow cytometry. Based on their excellent sensitivity and stability, and outstanding versatility, DANPY-NO@AuNPs can be applied for the spatiotemporal monitoring of in vitro and in vivo NO levels.
- Open Access
- 11 May 2022
- Published by IOP Publishing in Methods and Applications in Fluorescence
- Vol. 10 (3) , 034003
Recent advances in near infrared upconverting nanomaterials for targeted photodynamic therapy of cancer
Photodynamic therapy (PDT) is a well-established treatment of cancer that uses the toxic reactive oxygen species, including singlet oxygen (1O2), generated by photosensitiser (PS) drugs following irradiation of a specific wavelength to destroy the cancerous cells and tumours. Visible light is commonly used as the excitation source in PDT, which is not ideal for cancer treatment due to its reduced tissue penetration, and thus inefficiency to treat deep-lying tumours. Additionally, these wavelengths exhibit elevated autofluorescence background from the biological tissues which hinders optical biomedical imaging. An alternative to UV–Vis irradiation is the use of near infrared (NIR) excitation for PDT. This can be achieved using upconverting nanoparticles (UCNPs) functionalised with photosensitiser drugs where UCNPs can be used as an indirect excitation source for the activation of PS drugs yielding to the production of singlet 1O2 following NIR excitation. The use of nanoparticles for PDT is also beneficial due to their tumour targeting capability, either passively via the enhanced permeability and retention (EPR) effect or actively via stimuli-responsive targeting and ligand-mediated targeting (i.e. using recognition units that can bind specific receptors only present or overexpressed on tumour cells). Here, we review recent advances in NIR upconverting nanomaterials for PDT of cancer with a clear distinction between those reported nanoparticles that could potentially target the tumour due to accumulation via the EPR effect (passive targeting) and nanoparticle-based systems that contain targeting agents with the aim of actively target the tumour via a molecular recognition process.
- 11 May 2022
- Published by IOP Publishing in Methods and Applications in Fluorescence
- Vol. 10 (3) , 034003
Open AccessRecent advances in near infrared upconverting nanomaterials for targeted photodynamic therapy of cancer
Photodynamic therapy (PDT) is a well-established treatment of cancer that uses the toxic reactive oxygen species, including singlet oxygen (1O2), generated by photosensitiser (PS) drugs following irradiation of a specific wavelength to destroy the cancerous cells and tumours. Visible light is commonly used as the excitation source in PDT, which is not ideal for cancer treatment due to its reduced tissue penetration, and thus inefficiency to treat deep-lying tumours. Additionally, these wavelengths exhibit elevated autofluorescence background from the biological tissues which hinders optical biomedical imaging. An alternative to UV–Vis irradiation is the use of near infrared (NIR) excitation for PDT. This can be achieved using upconverting nanoparticles (UCNPs) functionalised with photosensitiser drugs where UCNPs can be used as an indirect excitation source for the activation of PS drugs yielding to the production of singlet 1O2 following NIR excitation. The use of nanoparticles for PDT is also beneficial due to their tumour targeting capability, either passively via the enhanced permeability and retention (EPR) effect or actively via stimuli-responsive targeting and ligand-mediated targeting (i.e. using recognition units that can bind specific receptors only present or overexpressed on tumour cells). Here, we review recent advances in NIR upconverting nanomaterials for PDT of cancer with a clear distinction between those reported nanoparticles that could potentially target the tumour due to accumulation via the EPR effect (passive targeting) and nanoparticle-based systems that contain targeting agents with the aim of actively target the tumour via a molecular recognition process.
- Open Access
- 6 April 2022
- Published by Springer Nature in Photochemical & Photobiological Sciences
- Vol. 21 (6) , 1111-1131
Recent advances in nanoparticle-based targeting tactics for antibacterial photodynamic therapy
The rise of antibacterial drug resistance means treatment options are becoming increasingly limited. We must find ways to tackle these hard-to-treat drug-resistant and biofilm infections. With the lack of new antibacterial drugs (such as antibiotics) reaching the clinics, research has switched focus to exploring alternative strategies. One such strategy is antibacterial photodynamic therapy (aPDT), a system that relies on light, oxygen, and a non-toxic dye (photosensitiser) to generate cytotoxic reactive oxygen species. This technique has already been shown capable of handling both drug-resistant and biofilm infections but has limited clinical approval to date, which is in part due to the low bioavailability and selectivity of hydrophobic photosensitisers. Nanotechnology-based techniques have the potential to address the limitations of current aPDT, as already well-documented in anti-cancer PDT. Here, we review recent advances in nanoparticle-based targeting tactics for aPDT. Graphical
- 6 April 2022
- Published by Springer Nature in Photochemical & Photobiological Sciences
- Vol. 21 (6) , 1111-1131
Open AccessRecent advances in nanoparticle-based targeting tactics for antibacterial photodynamic therapy
The rise of antibacterial drug resistance means treatment options are becoming increasingly limited. We must find ways to tackle these hard-to-treat drug-resistant and biofilm infections. With the lack of new antibacterial drugs (such as antibiotics) reaching the clinics, research has switched focus to exploring alternative strategies. One such strategy is antibacterial photodynamic therapy (aPDT), a system that relies on light, oxygen, and a non-toxic dye (photosensitiser) to generate cytotoxic reactive oxygen species. This technique has already been shown capable of handling both drug-resistant and biofilm infections but has limited clinical approval to date, which is in part due to the low bioavailability and selectivity of hydrophobic photosensitisers. Nanotechnology-based techniques have the potential to address the limitations of current aPDT, as already well-documented in anti-cancer PDT. Here, we review recent advances in nanoparticle-based targeting tactics for aPDT. Graphical
- Open Access
- 3 November 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 50 (45) , 16739-16750
Precious metal complexes of bis(pyridyl)allenes: synthesis and catalytic and medicinal applications
Bis(pyridyl)allenes: unique 3D scafolds for novel metal coordination complexes with unreported applications in catalysis and as metallodrugs.
- 3 November 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 50 (45) , 16739-16750
Open AccessPrecious metal complexes of bis(pyridyl)allenes: synthesis and catalytic and medicinal applications
Bis(pyridyl)allenes: unique 3D scafolds for novel metal coordination complexes with unreported applications in catalysis and as metallodrugs.